North America CAR T-Cell Therapy Market Size, Share & Forecast, By Product Type, Disease Area & Country, 2026-2031

The market was valued at USD 4,420 million in 2025. The estimate represents manufacturer net revenue from commercial CAR T-cell therapies administered in the United States, Canada and Mexico. Approximately 9,820 commercial infusions were completed during the year, implying average net therapy revenue of about USD 450,000 per infusion. The United States accounted for the majority of regional activity because it had seven approved products, the broadest payer coverage and more than 250 treatment locations across overlapping manufacturer networks.

The market is forecast to reach USD 12,330 million by 2031, representing a CAGR of 18.65% from 2025. Commercial infusion volume is expected to expand to approximately 28,500 treatments, supported by earlier-line approvals, additional lymphoma and myeloma indications, greater outpatient use and larger authorized-center networks. Growth is expected to moderate from the unusually high 2020-2025 rate as the revenue base expands and competition creates pressure on net price realization.

The largest incremental profit pool will develop in earlier-line multiple myeloma, followed by broader lymphoma indications and outpatient delivery. BCMA-directed Carvykti generated USD 1.9 billion in global net trade sales in 2025, demonstrating the value of moving into larger eligible populations. Additional value will accrue to manufacturers that reduce turnaround time and to hospitals that operate high-throughput outpatient programs. Longer-term profit pools may shift toward allogeneic and in vivo products if they achieve efficacy comparable to autologous treatments.

The principal constraint is the combination of patient-specific manufacturing, high episode cost and specialist-care requirements. Autologous production can require two to four weeks, while total Medicare inpatient episode costs have averaged close to USD 499,000. Patients with rapidly progressing disease may become ineligible while waiting, and hospitals can face reimbursement timing or outlier-payment exposure. Safety monitoring for cytokine-release syndrome and neurologic toxicity also limits rapid decentralization into lower-acuity settings.

The United States ranks first among relevant peers, with an estimated USD 4,050 million market in 2025. Canada followed within North America at approximately USD 310 million, while Mexico remained an early-stage commercial market near USD 60 million. The United States benefits from seven approved products, more than 150 Yescarta centers, more than 140 Carvykti centers and established Medicare payment mechanisms. Canada has strong academic capabilities but fewer treatment sites and fragmented provincial funding pathways.

Earlier-line use within a large recurring blood-cancer population will have the greatest demand impact. The United States expected 192,070 new leukemia, lymphoma and myeloma diagnoses in 2025, including 89,070 lymphoma cases. Only a fraction currently receives CAR T-cell therapy because of eligibility, referral, capacity and reimbursement barriers. Moving products into earlier treatment lines raises the eligible share, improves patient fitness at referral and allows manufacturers to serve patients before aggressive disease progression prevents treatment.